Suven Life Sciences Ltd (SUVEN) is currently trading at 280.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of novel therapeutics for central nervous system (CNS) disorders, operating through its India parent and wholly owned US subsidiary Suven Neurosciences, Inc., with R&D and clinical development as the single business segment. Financially, FY2026 consolidated results show a large net loss of Rs.27,634.41 lakhs driven by elevated R&D and operational spend, while the company raised substantial equity via a preferential issue (proceeds ~Rs.75,715.41 lakhs) that materially strengthened cash and investment balances and funded near-term clinical programs. Pipeline momentum is a key positive: SUVN-502 (Masupirdine) reached 76% enrollment in a global Phase 3 agitation in Alzheimer’s dementia trial with enrollment expected to complete by end-2026 and readout potentially in mid-late 2027; SUVN-G3031 entered global Phase 3 for excessive daytime sleepiness in narcolepsy, showing clear clinical progress. Suven reported seven patents granted during the period across major jurisdictions and completed several IND/Phase transitions (IND for Usmarapride, Phase 2B complete for Ropanicant), confirming a consistent R&D output and patent protection strategy that underpins its CNS-focused pipeline and long-term value creation potential. Key corporate items include a large preferential allotment process executed in 2025–26 with partial conversions and an outstanding warrant receivable balance of Rs.9,331 lakhs, Board emphasis on regulatory compliance after exchange levies were waived, and the commissioning of new facilities in Genome Valley to support R&D scale-up.

Over the past 52 weeks, Suven Life Sciences Ltd has traded between a low of ₹124.35 and a high of ₹402.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Suven Life Sciences Ltd has a market capitalization of approximately 7,855.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Suven Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -20.56 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,855.24 Cr, Suven Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Suven Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Suven Life Sciences Ltd is -20.56. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Suven Life Sciences reported a consolidated net loss of Rs 106.9421 crore for the quarter ended September 30, 2026. The loss was Rs 77.3099 crore in the quarter ended September 30, 2025 and Rs 127.6103 crore in the June 2026 quarter.

Suven expects potentially to report Masupirdine topline data in Q2 of calendar year 2027. The company expects the last patient last visit in Q1 2027, allowing the study to progress towards database lock before reporting.

Suven converted 1,85,70,133 fully paid preferential warrants into the same number of equity shares during the quarter ended September 30, 2026. The conversion involved 17 allottees and followed receipt of full warrant consideration.

Suven Life Sciences Ltd has scheduled its board meeting for November 5, 2026. The board will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.